California Public Employees Retirement System maintained its stake in Cascadian Therapeutics, Inc. (NASDAQ:CASC) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,832 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. California Public Employees Retirement System owned about 0.06% of Cascadian Therapeutics worth $103,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Cascadian Therapeutics by 116.7% in the 1st quarter. Vanguard Group Inc. now owns 1,423,843 shares of the biopharmaceutical company’s stock valued at $5,895,000 after purchasing an additional 766,725 shares during the last quarter. Sandia Holdings LLC boosted its stake in shares of Cascadian Therapeutics by 70.5% in the 2nd quarter. Sandia Holdings LLC now owns 927,264 shares of the biopharmaceutical company’s stock valued at $3,445,000 after purchasing an additional 383,545 shares during the last quarter. Boston Partners bought a new position in shares of Cascadian Therapeutics in the 2nd quarter valued at about $1,412,000. Northern Trust Corp boosted its stake in Cascadian Therapeutics by 415.5% during the 2nd quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock worth $1,420,000 after acquiring an additional 308,270 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Cascadian Therapeutics by 920.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 205,178 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 185,081 shares during the last quarter. 80.35% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) opened at $4.04 on Tuesday. Cascadian Therapeutics, Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $6.72.

Cascadian Therapeutics (NASDAQ:CASC) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. During the same quarter last year, the company earned ($0.09) EPS. sell-side analysts anticipate that Cascadian Therapeutics, Inc. will post -1.27 earnings per share for the current year.

Several research analysts recently weighed in on CASC shares. Cowen reissued a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, August 9th. Zacks Investment Research lowered shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price objective on shares of Cascadian Therapeutics in a research note on Thursday, August 31st. ValuEngine lowered shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Barclays initiated coverage on shares of Cascadian Therapeutics in a research note on Wednesday, September 6th. They set an “underweight” rating and a $4.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $5.63.

WARNING: This article was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://theolympiareport.com/2017/12/05/cascadian-therapeutics-inc-casc-holdings-held-by-california-public-employees-retirement-system.html.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.